The global buccal drug delivery systems market size is expected to reach USD 5.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.2% from 2021 to 2028. Buccal drug delivery systems have gained significant momentum since the last decade. Elimination of first-pass metabolism, quick absorption of the pH-sensitive drug, no interaction with stomach acid, quicker onset of action than any oral dose, minimal side effects, and reduced drug degradation are some of the factors fueling the market growth. Buccal drug delivery has gained large acceptance among geriatric patients and patients having difficulty swallowing.
Leading players like Generex, NovaDel, Biodiversity Sciences International, and Transcept Pharmaceuticals are constantly developing critical drugs like insulin, heparin, morphine, long-lasting pain analgesics, and some anti cardiac drugs into rapid mists, mucoadhesive discs, and lozenges. Commercialization of this research would eventually lead to being a major life savior as it would ensure the faster onset of action and eliminate drug degradation. Despite the increased R&D activity among market players, asteep decline was observed in the sales and revenue gainsdue to the outbreak of the Covid-19 pandemic. Except for covid medications, several other drug markets were majorly hit leading to the dip in the market for buccal drug delivery. However, it is expected to bounce back by 2022.
Request a free sample copy or view report summary: Buccal Drug Delivery Systems Market Report
The buccal tablets and lozenges type segment accounted for the largest revenue share in 2020 due to its wider acceptance among patients
The smoking cessation application segment held the largest share in 2020. Buccal drug delivery is often the most preferred and effective formulation for treating patients with smoking or nicotine addiction
The hospital end-user segment captured the largest revenue share in 2020 owing to a large number of admissions of geriatric patients and abundant medication supplies
North America held the largest revenue share in 2020 due to a large number of leading manufacturers and growing research in the region
Grand View Research has segmented the global buccal drug delivery systems market on the basis of type, application, end-user, and region:
Buccal Drug Delivery Systems Type Outlook (Revenue, USD Million, 2016 - 2028)
Buccal Tablets and Lozenges
Buccal Drug Delivery Systems Application Outlook (Revenue, USD Million, 2016 - 2028)
Buccal Drug Delivery Systems End-user Outlook (Revenue, USD Million, 2016 - 2028)
Buccal Drug Delivery Systems Regional Outlook (Revenue, USD Million, 2016 - 2028)
Middle East & Africa
List of Key Players of Buccal Drug Delivery Systems Market
Teva Pharmaceutical Industries Ltd.
BioDelivery Sciences International, Inc.
Cynapsus Therapeutics Inc.
Endo Pharmaceuticals plc
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
"The quality of research they have done for us has been excellent..."